Skip to main content
Premium Trial:

Request an Annual Quote

Ag-Bio Startup Amfora Licenses CRISPR IP From Corteva, Broad Institute

NEW YORK (GenomeWeb) — Ag-bio startup Amfora announced today that it has acquired a nonexclusive license to intellectual property covering CRISPR-Cas9 genome editing and related technologies from DowDuPont's Corteva Agriscience and the Broad Institute.

San Francisco-based Amfora, which closed a $5 million Series A round roughly two years ago, aims to develop nutritionally enhanced food and feed crops. Under the terms of the license, Amfora will be able to use the IP to develop crops with increased protein content.

Additional terms were not disclosed.

"The CRISPR-Cas9 patent estate is a proven technology that we can use to develop our products," Amfora CSO Michael Lassner said in a statement. "Securing this license will allow us to effectively use our proprietary technology."

Earlier this year, Amfora said that it won a $350,000 grant from the United Soybean Board to develop soybean varieties with increased protein content.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.